Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-related Adverse Events
研究概览
简要总结
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell Lymphoma.
详细描述
Lymphoma is a malignant tumor originating from lymph nodes or other lymphoid tissues. It can be divided into B cells, T cells, and NK cell lymphomas depending on the origin of different lymphocytes. Among them, B cell lymphoma accounts for about 90% of lymphoma.
Chimeric antigen receptor T (CART) cells is a promising treatment for lymphoma. T lymphocytes from patients are separated and engineered with CD19-CAR, to specifically recognize and eliminate CD19-positive tumor cells. At present, many CD19CART cells therapy studies are in the stage of clinical research and have achieved significant clinical effects.
Although there are some CD9CART cells clinical trials, the therapeutic effect on lymphoma is significantly lower than that of acute leukemia. One of the reasons is that lymphoma has the nature of solid tumors, whichi has a certain immunosuppressive microenvironment. The clinical trials of anti-PD-1 antibody drugs against lymphoma also show good therapeutic efficacy. Therefore, the combination of anti-PD-1 or PD-L1 antibody and CD19CART is one of the ways to improve the therapeutic effect of CART cells.
The investigators screened PD-1 mutants that have high bind with the PD-L1 ligand, and prepared CD19CART which secretes the mutant PD-1Fc fusion protein. Preclinical studies have shown that CD19CART cells secreting mutant PD-1Fc fusion protein have a superior killing effect to CD19CART cells which does not express PD-1 fusion protein.
The trial was conducted to explore the safety and efficacy of CD19-PD1-CART cells in Relapsed/Refractory B Cell Lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged 14 to 80 years (including 14 and 80 years old).
- •The diagnosis was Refractory/relapsed B-cell lymphoma.(Meeting 1 of the first 4 items plus item 5)
- •A.Tumor shrinkage less than 50% or disease progression after 4 cycles of standard chemotherapy.
- •B.Achieved CR after standard chemotherapy, but relapsed within 6 months.
- •C.2 or more relapses after CR.
- •D.Not suitable for HSCT, or relapse after HSCT.
- •E.Subjects must have received adequate treatment in the past and the predicted survival is more than three months.
- •Patient or his or her legal guardian voluntarily participates in this stuy and signs an informed consent form.
- •Flow cytometry or immunohistochemistry showed CD19 positive in tumor cells.
- •No serious concomitant disease and major organ function is not serious abnormal.
- •ECOG physical condition score 0-3 or KPS score >
- •the test meets the following indicators:
- •A.ALT/AST < 2.5 times the upper limit of normal (ULN) and total bilirubin≤34.2μmol/L.
- •B.Creatinine < 176.8 μmol/L.
- •C.WBC≥2.5×109/L ，LY≥0.7×109/L，LY%≥15%.
- •D.PT/INR < 1.7 or PT was extended by less than 4 seconds.
排除标准
- •Women who are pregnant or breastfeeding.
- •Patients whose tumor cell don't have positive CD19 antigen.
- •Active hepatitis B or hepatitis C, HIV/AIDS infection, any uncontrolled active infection.
- •Patients who are using steroid drugs throughout the body currently.
- •Patients who have received any gene therapy in the past.
- •Patients who are allergy to immunotherapy and related drugs.
- •Patients with heavy heart disease or poorly controlled high blood pressure.
- •Patients who received chemotherapy or radiation 4 weeks before the study began.
- •Patients who are participating in other clinical trials.
结局指标
主要结局
Incidence of Treatment-related Adverse Events
时间窗: 3 years
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0).
次要结局
- Overall Remission Rate(ORR) of CD19-PD1-CART cells in Lymphoma(3 years)
- Overall survival(OS) of CD19-PD1-CART cells in Lymphoma(3 years)
- Rate of CD19-PD1-CARTcells in peripheral blood cells(3 years)
- Quantity of CD19-PD1-CART cells copies in peripheral blood cells.(3 years)
- Progress-free survival(PFS) of CD19-PD1-CART cells in Lymphoma(3 years)
研究者
Quanshun Wang
Chief of Hematology Department of Hainan Hospital of PLA General Hospital; Vice Chief of Hematology Department of PLA General Hospital
Chinese PLA General Hospital